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Plasminogen activator (PA)' is produced and secreted by mouse and human
monocytes and neutrophils (1-4) . A role for the enzyme in cell migration
associated with inflammation has been postulated (5) . Recently, a specific PA
receptor on the surface of monocytes has been described (6, 7) . PA bound to
this receptor remains active, providing a mechanism through which a cell can
concentrate proteolytic activity on its membrane . This finding suggests PA
participation in processes requiring direct, local proteolysis.
It has been shown that PA activity of macrophages and neutrophils can be
modulated by agents such as Con A, PMA, or glucocorticoids (1, 3, 5) . In these
experiments, long-term effects were studied and the enzyme was measured either
in whole cell lysates or in the conditioned medium . In a number of other studies
(8-12) involving thymocytes, macrophages, basophils, and several tumor cell
lines, the subcellular localization of PA has been examined but no uniform
conclusion has been reached, nor was a comparison ofsubcellular PA distribution
in resting and activated states in neutrophils or any other cells attempted .
Using a previously published method (13) of neutrophil fractionation, we
obtained highly enriched fractionsofazurophilicand specific granulesand plasma
membranes, and we determined PA activity in these fractions . We compared the
localization of PA in resting and activated neutrophils.
Our results provide evidence that in resting neutrophils most of PA is associ-
ated with the specific granule membranes, and upon activation, PA translocates
to the plasma membrane, thus equipping the neutrophil with surface-associated
proteolytic activity .
Materials and Methods
Materials .
￿
Human blood for isolation of neutrophils was obtained from healthy vol-
unteers . Ficoll, Percoll, Sepharose 4B, and calibration beads were from Pharmacia Fine
Chemicals (Piscataway, NJ) . Hypaque was from Winthrop Laboratories (New York, NY);
Triton X-100 was from Fisher ScientificCo . (Fair Lawn, NJ) ; "'Co-vitamin B12 and Na1251
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' Abbreviations used in this paper:
￿
PA, plasminogen activator, tPA, tissue-type plasminogen acti-
vator, uPA, urokinase-type plasminogen activator, UK, urokinase .
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were from New England Nuclear (Boston, MA); and ATP (Na)2 was from Boehringer
Mannheim Biochemicals (Indianapolis, IN). We obtained PMA, p-nitrophenyl phosphate,
phenolphthalein 0-monoglucuronic acid, DFP, and fibrinogen (77% clotting ability) from
Sigma Chemical Co. (St. Louis, MO) and chromogenic substrate for urokinase (UK), the
L-pyroglutamyl-glycyl-L-arginine-p-nitroanilide (S 244 Spectrozyme UK), from American
Diagnostica (Greenwich, CT). UK for standards was from Leo Pharmaceuticals (Ballerup,
Denmark); plasmin was from Kabi Diagnostica (Stockholm, Sweden); Trasylol (aprotinin)
was from FBA Pharmaceuticals (New York, NY). Antibodies to UK- and tissue-type PA
(uPA and tPA) were prepared by injecting rabbits with purified antigens, as described
(14). All other materials were of reagent grade.
Isolation and Fractionation of Neutrophils.
￿
Isolation and fractionation of neutrophils
were essentially as described (13). Briefly, after dextran sedimentation of red cells,
leukocyte-rich fractions from blood of healthy donors were centrifuged through Ficoll
Hypaque as described (13), and the residual red blood cells were lysed by osmotic shock.
For disruption, neutrophils were resuspended in relaxation buffer (100 mM KCI, 3 mM
NaCI, 1 mM ATP(Na)2, 3 .5 mM MgC12, 10 mM Pipes, pH 7.3) at 1-5 x 107 cells per ml
and pressurized with N2 at 350 psi for 20 min at 4°C in a nitrogen bomb. Nuclei and
unbroken cells were removed by centrifugation and the postnuclear supernatants were
further fractionated on a discontinuous Percoll gradient (14 ml of Percoll, density 1 .120
layered under 14 ml of Percoll, density 1 .050 gm/ml, 22 min at 48,000 g, 4°C). The
density of the different fractions was estimated from calibration beads centrifuged on a
parallel gradient. I-ml fractions were collected and assayed for protein content (15), (0-
glucuronidonase activity (16), vitamin B12-binding protein content (17), and alkaline
phosphatase activity (18). In some experiments (Figs. l, 3, and 5), PA in the presence of
plasminogen, and fibrinolytic activity in the absence of plasminogen were assayed in each
individual fraction ; in all other experiments the enzyme activities were determined in
pools of the fractions under each major peak.
To reexamine the association of PA with the vitamin B12-binding protein marker,
those fractions from the original Percoll gradient that contained vitamin B12-binding
protein were pooled (total volume, 17.0 ml), diluted with relaxation buffer (final volume,
23 ml), and recentrifuged (48,000 g for 22 min at 4°C). All fractions (0.5 ml each) were
reassayed for PA and vitamin B 12-binding protein content.
Assays.
￿
fl-glucuronidase (EC 3 .2.1 .31) was assayed exactly as described (16) by mea-
suring the liberation of phenolphthalein from 1 mM phenolphthalein monoglucuronic
acid; vitamin B12-binding protein was quantitated as described (17) using 57Co-cyanoco-
balamin . In alkaline phosphatase (EC 3.1 .3 .1) assays, paranitrophenyl phosphate was used
as substrate (18). PA activity was measured as previously described (19), using a two step
assay in which PA converts plasminogen to plasmin, which in turn degrades "5I-fibrin.
The assay mixture, which was incubated in wells coated with "'I-labeled fibrin, contained
an aliquot of the gradient fractions (usually 10 tcl), 300 /l of 0.1 M Tris-HCI buffer (pH
8.1), and 7 wg/ml of purified human plasminogen (20). The reaction mixtures were
incubated at 37'C, and aliquots were removed at different times for counting. The
fibrinolytic activity was measured under identical conditions, but no plasminogen was
added to the incubation mixtures. Routinely, all assays were carried out in the presence
of 0.01% Triton X-100.
Zymography and Inhibition of PA Activity by Antibody.
￿
This procedure, which reveals
proteolytic enzyme activity after separation on SDS-PAGE and exposure to an indicator
gel, was performed exactly as described (21), except that instead of fibrin, 2% casein was
used in the gel overlays. In zymography, the molecular weight and the activity of an
enzyme in a given sample can be identified by comparison with a standard sample of
known activity. We also examined the type of PA by using antibodies that specifically
inhibit the catalytic activity of either tPA or of uPA. 40 Al aliquots of specific granules
and of plasma membranes were mixed with equal volumes of rabbit anti-human uPA or
anti-human tPA antibodies (200 fag/ml); standard preparations of human uPA or condi-
tioned medium from human melanoma-producing tPA, served as controls. The mixtures828 TRANSLOCATION OF HUMAN NEUTROPHIL PLASMINOGEN ACTIVATOR
were incubated for 40 min at 4°C, and aliquots of the different reaction mixtures were
assayed on radioactive fibrin plates for residual PA activity .
Disruption of Granules.
￿
To separate the content of specific granules from their mem-
brane components we used the technique described previously (13), in which most of the
vitamin B12-binding protein (a soluble component) was liberated into the supernatant
upon freezing and thawing . Samples were frozen and thawed three times in succession by
transferring them from room temperature to -20'C . The membranes were separated by
centrifugation (220,000 g at 4°C) . The supernatants and the membranes were assayed
for vitamin B12-binding protein content and PA . All the assays for PA were performed
in the presence of 0.01 % (final concentration) of Triton X-100 .
DFP Treatment .
￿
Before cavitation, the purified neutrophils were incubated with 3 mM
DPF for 15 min on ice, then the cells were pelleted and the DFP-containing supernatants
were discarded .
Activation of Neutrophils .
￿
After DFP treatment, the neutrophils were resuspended in
20 ml ice-cold, isotonic phosphate buffer (pH 7.4) with 3 mM glucose, and were divided
into two equal fractions . 20 ng/ml PMA in DMSO (final concentration 0.007%) was added
to one fraction, and the cells were incubated at 37°C for 15 min . Controls, incubated
under identical conditions, received only DMSO . The samples were agitated every 5 min,
and at the end of incubation they were plunged into ice water and centrifuged (800 rpm)
for 10 min at 4'C . Each pellet was resuspended in 10 ml of relaxation buffer and subjected
to cavitation and fractionation as described above .
To test the activity of intact neutrophils, aliquots containing 5 x 106 of resting and
activated cells (prepared exactly as above, but not treated with DFP before activation)
were incubated for 30 min at 37°C in 100,l of isotonic phosphate buffer with or without
1 mg/ml ofhuman plasminogen . After incubation, supernatants of cells not exposed to
plasminogen were mixed with 1 mg/ml ofplasminogen and incubated for 30 min at 37'C .
10-,1 aliquots of each supernatant were assayed for fibrinolytic activity .
Assay ofPro-UK .
￿
The assay was carried out essentially as described (14). 100-,l samples
to be tested were mixed with synthetic, chromogenic substrate (S 244), which measures
the amidolytic activity of UK . Pro-UK does not have any measurable, amidolytic activity,
and only after activation with catalytic amounts of plasmin does it become active (14, 22) .
We tested the amidolytic activity of samples both in the presence and absence of plasmin,
and also in the presence and absence of 10 U/ml ofTrasylol . The rest ofthe experimental
procedures were as suggested by the supplier of S 244 substrate, except that all samples
were centrifuged at the end of incubation to remove some precipitated material . Standard
UK curves of 0.05-5 U were included in all assays .
Results
It has been shown previously (13) that the conditions used for cavitation and
fractionation allow the different organelles of the neutrophil to equilibrate at
their isopycnic densities, and result in minimal damage to the granule mem-
branes . We have followed this procedure in detail and found that our separation
profiles were very similar to those published (13) .
Localization ofPA and Plasminogen-independent Fibrinolytic Activity in Resting
Neutrophils . Fractions obtained from Percoll gradients were analyzed for their
content of #-glucuronidase, vitamin B12-binding protein, and alkaline phospha-
tase . The marker for specific granules (vitamin B 12-binding protein) was found
in a very sharp, well-defined peak (Fig . IA), which equilibrated between 1 .06
and 1 .10 gm/ml of Percoll . As shown previously (13), we found that ^.25% of
the recovered (3-glucuronidase cofractionated with the specific granule fractions
(Fig . 1 A) . As suggested earlier (13), this value is probably an overestimate since
the high Percoll concentration in the fractions containing most of the 0-glucu-
ronidase activity is inhibitory for the enzyme assay .o° 0.3
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FIGURE 1.
￿
Distribution ofenzyme markers(A)andPA andfibrinolytic activity (B) infractions
fromadiscontinuous Percollgradient. (A)Postnuclear supernatant (see Materialsand Methods)
was layered on a discontinuous Percoll gradient,and after centrifugation 1-ml fractions were
collectedby aspiration from thebottom of thegradient. Aliquots of each sample were assayed
for S-glucuronidase, vitamin B12-binding protein, and alkaline phosphatase (see Materials
and Methods). (B) Undilutedaliquots (10 Al)were assayed forPA and fibrinolytic activity. The
resultsare the average of two determinations which did not vary by >5%. The resultsshown
are from cells that were incubated for 15 min at 37°C before cavitation. The plasma
membrane-associated PA activity was 40% of the total.
PA activity was determined in every fraction across the gradient. This activity
was concentrated in two areas that corresponded to the specific granule and the
plasma membrane peaks (Fig. 1 B). Routinely, only a minor fraction of PA
activity (0-21% in five individual experiments) was associated with the plasma
membrane; the rest (79-100% of total PA activity) was in the specific granules
(Table 1). No PA activity was detected in the azurophilic granules (Fig. 1 B).
From the comparison of results illustrated in Figs. 1, A and B, it was apparent
that the distribution of PA and vitamin B12-binding protein was very similar,
suggesting that the two proteins reside in the same subcellular compartment.
Plasminogen-independent fibrinolytic activity was predominantly associated with
the azurophilic granules (Fig. 1B); a small part ofthe activity cofractionated with
a portion ofthe specific granule peak (Fig. 1B).
Due to the possibility of the presence of other granule compartments in the
specific granule fractions (23), we reexamined the association of PA with the
specific granules bypooling the fractions containing vitamin B12-binding protein
from the original Percoll gradient, and then diluting and recentrifuging the
pooled fractions. As shown in Fig. 2, under experimental conditions designed to
improve the separation ofspecificgranule fractions, PAandvitamin B12-binding830 TRANSLOCATION
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10-,al aliquots of pooled fractions of specific granules and plasma mem-
branes isolated from cavitates in five individual experiments were assayed
for PA activity. The numbers represent total PA activity in the specific
granules or in theplasma membranes; thecalculation is basedon duplicate
assays that differed by <10%.
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Characterization ofPA.
￿
To characterize the type of PA produced by neutro-
phils, we chromatographed aliquots taken from pooled fractions of each of the
three major cytoplasmic organelles on SDS-PAGE, removed the SDS, and
posed the gel toan indicator overlay that contained casein and plasminogen {2
Lysis zones in the overlay corresponded to the areas where PA was present in
ge}. No lysis zones farmed in lanes that contained aliquots ofthe azurophilic
granules (Fig. 3, lane 2). As explained below, serine proteases, such as elastase
and chymotrypsin, were inhibited by the pretreatment of neutrophils with DFP
before cavitation. Aliquots ofspecific granules and plasma membranes produced
lysis zones (Fig. 3, lanes 3 and 4). The specific granules had more activity than
plasma membranes. This activity comigrated with that of a standard
ry UK (lane 5) and not with tPA (lane I), suggesting that the PA presen
Exp.
Plasminogen
granules
activator(mU UK)in.
1 1,890 279 12.9
2 2,160 0 0
3 549 150 21A
4 1,500 12 0.8
5 1,800 66 3.5HEIPLE AND OSSOWSKI
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FIGURE 3 .
￿
Identification of PA-type in the different cellular fractions . 10 ml aliquots ofpeak
fraction of azurophilic granules, specific granules, plasma membranes, and 10 1l of -1 U/ml
of uPA (human urinary UK) and tPA (human melanoma-conditioned medium) were electro-
phoresed on SDS-PAGE. The gel was washed for 1 h in Triton X-100 and incubated for 11 h
on top of an indicator gel that contained casein and plasminogen . Light bands represent lysis
zones in the indicator gel . Lane 1, tPA ; lane 2, azurophilic granules ; lane 3, specific granules ;
lane 4, plasma membranes ; lane 5, uPA. Aliquots of subcellular fractions were derived from
neutrophils exposed to DFP, a treatment that greatly reduces the content of serine proteases
in the azurophilic granules (lane 2) . Molecular mass markers are shown .
in both organelles was of the UK type . We reconfirmed this result by showing
that the catalytic activity ofthe enzyme obtained from specific granules and from
plasma membranes of neutrophils can be completely inhibited by antibodies to
human UK (Table 1I) .
The Effect ofDFP Pretreatment on Plasminogen-independent Fibrinolysis and on
the Recovery of PA Activity . Our standard fractionation procedure included a
step in which isolated, intact neutrophils were exposed to a brief treatment (15
min at 4°C) with 3 mM DFP. Without DFP pretreatment the fractionation
pattern of markers other than PA was not altered . However, none or only a
trace of PA activity, associated exclusively with the plasma membrane fractions,
could be recovered from these cells (Fig . 4) . In the cells not pretreated with DFP
the total plasminogen-independent fibrinolysis, associated mainly with the azur-
ophilic, and to a much lesser degree with the specific granule fractions, was
increased by about sevenfold (Fig . 4) . The difference in fibrinolytic activity
between the DFP pretreated and untreated cells showed that, in addition to PA,
neutrophils contain a major serine protease activity, and that the different
subcellular compartments in which these proteases reside are accessible to DFP.
We resolved the paradox of PA remaining active in cells pretreated with DFP
by showing that PA was stored in these cells in a pro-enzyme, single-chain form
(Table 111) . Pro-UK does not have detectable amidolytic activity when assayed
with a specific, chromogenic substrate (14, 22, 24). It can be converted to an
active form through catalytic activity of plasmin (14) . As can be seen in Table
111, aliquots of specific granules and plasma membranes were devoid of activity
unless incubated with catalytic amounts of plasmin. Trasylol (which inhibits
plasmin activity and therefore the conversion of pro-UK to active enzyme)
completely inhibited the cleavage of the chromogenic substrate ; plasmin alone832 TRANSLOCATION OF HUMAN NEUTROPHIL PLASMINOGEN ACTIVATOR
TABLE II
The Effect ofAnti-uPA and Anti-tPA Antibodies on PA in Specific
Granules and Plasma Membranes
40-,uI aliquots of neutrophil-specific granules from resting cells, plasma
membranesfrom activatedcells, human uPA and human tPA were mixed
with equalvolumesofanti-uPA or anti-tPA rabbit IgG(200 ug/ml) diluted
in phosphate buffer with 1 mg/ml BSA. The mixtures were incubated for
40 min at 4°C. Duplicate aliquots (10 jl) were assayed for PA activity in
radioactive fibrin plates. The variability between duplicates was always
<5%.
did not cleave the substrate. Results similar to those presented in Table III were
obtained with aliquots of plasma membranes from resting neutrophils (results
not shown). The specific granule PA of activated neutrophils was below the level
of detection in this assay.
Localization of PA Within Specific Granules.
￿
Freezing and thawing granules,
conditions which release the majority of the vitamin B12-binding protein from
the granule matrix, failed to release PA into the supernatant fraction. In three
out of three experiments, 100, 78, and 73% of PA activity remained associated
with the granule membranes.
Distribution of PA in Activated Neutrophils.
￿
It has been previously established
(25) that activation of neutrophils with 8 X 10-8 M PMA can induce selective
exocytosis of specific granules. Since PA was found to be associated with this
compartment, we were interested in examining whether activation could alter
the pattern of its distribution .
Isolated neutrophils were pretreated with DFP, one aliquot was treated with
PMA, the other served as control. Both were incubated at 37°C for 15 min and
subsequently subjected to standard fractionation procedures. We found that
PMA treatment caused a dramatic reduction (from >70 down to <14%) in PA
activity of specific granules. This reduction was similar to that found in vitamin
B12-binding protein when granules from resting neutrophils were compared
with activated cell granules, (Fig. 5).
Source of PA IgG PA Inhibition
(mU/ml) (%)
Specific granules None 229.0 -
Anti-uPA 0.0 100.0
Anti-tPA 228.0 0.4
Plasma membranes None 248.0 -
Anti-uPA 0.4 99.8
Anti-tPA 251.0 0.0
uPA None 385.0 -
Anti-uPA 7.4 98.1
Anti-tPA 367.0 4.7
tPA None 301.0 -
Anti-uPA 298.0 1.0
Anti-tPA 2.8 99.1HEIPLE AND OSSOWSKI
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FIGURE 4.
￿
PA and fibrinolytic activity in azurophilic granules obtained from neutrophils not
pretreated with DFP. Neutrophils were isolated exactly as describedin Materialsand Methods
except that they were not pretreated with DFP before cavitation. The fractionation on
discontinuous Percoll gradient andassays were done exactly as in Fig. 1, A and B. (O) PA, (N)
fibrinolytic activity. For comparison, fibrinolytic activity present in fractions from DFP-
pretreated cells (shown in Fig. 1 B) is also represented (p).
TABLE III
Amidolytic Activity ofPA from Specific Granules and Plasma
Membranes
100-;t1aliquots ofpeak fractions(specific granules or plasma membranes)
were mixed with Spectrozyme S-244, some samples were mixed with 1
Wg of plasmin in thepresence or in theabsence of 10 U of Trasylol, the
volume wasbrought up to 1 ml with phosphate buffer (pH 7.4), and the
samples were incubated for 2 h at 37°C. Optical density was measured
at 405 rim. Unit values were calculated from a standard, UK curve of
0.05-50 U.
* Unitsper fraction amidolytic activity.
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In this experiment, plasma membranes of control neutrophils contained 27%
of the total PA. This value (and the value shown in Fig. 1 B) are somewhat
greater than the values in Table 1. In these experiments the resting neutrophils
were incubated for 15 min at 37°C, conditions which may have caused partial
activation. While most of the vitamin B12-binding protein was found in the
supernatant of the activated cells (not shown and reference 13), >85% of the
Neutrophil fraction Sample
alone
Reaction
Sample
with plas-
min
mixtures*
Sample with
plasmin and
Trasylol
Plasmin
alone
Specific granules <0.05 2.6 <0.05 <0.05
(Resting)
Plasma membranes <0 .05 2.2 <0 .05 <0.05
(Activated)834 TRANSLOCATION OF HUMAN NEUTROPHIL PLASMINOGEN ACTIVATOR
FIGURE 5. Translocation of PA from specific granules to plasma membranes . Isolated
neutrophils were divided into two parts ; one was exposed to 20 ng/ml ofPMA for 15 min at
37°C, the other served as a control. After cavitation and separation on a Percoll gradient,
each fraction was assayed for specific markers and PA activity . The results show activities in
pooled peak fractions of specific granules and plasma membranes, and are expressed as the
percent of total activity . For comparison, vitamin B12-binding protein content in control and
activated neutrophils was assayed in parallel . (M)B12-binding protein, (p), PA .
total PA activity was found in the plasma membrane fractions . This would be
expected of a protein which appears to be associated with the specific granule
membrane, and indicates that during activation PA translocates from the specific
granule to the plasma membrane . PA from activated neutrophils (both in specific
granules and in plasma membranes) was of the uPA type, asjudged by zymog-
raphy (not shown) and by inhibition by specific antibody (Table II) .
Cell Surface-associated PA in Resting and Activated Neutrophils .
￿
To assess the
cell surface-associated PA activity of intact cells, restingandactivatedneutrophils
were incubated for 30 min at 37°C in the presence or absence of 1 mg/ml of
plasminogen . The activation of neutrophils was carried out exactly as described,
except that in this experiment, the cells were not pretreated with DFP. Aliquots
of supernatants containing plasminogen were assayed directly for fibrinolytic
activity . Supernatants of cells incubated in absence of plasminogen were first
mixed with 1 mg/ml of plasminogen, incubated for 30 min at 37°C, and only
then assayed for fibrinolytic activity . No detectable activity was found in the
samples obtained from cells incubated in the absence of plasminogen, regardless
of the state of activation of the cells. This indicates that no PA was released into
the supernatants during the 30 min incubation period . In contrast, the super-
natants from cells incubated in the presence of plasminogen had measurable
levels of fibrinolytic activity . More importantly, the activated neutrophils were
12-fold more efficient than the resting cells in converting plasminogen to plasmin
Table IV, indicating the presence of an active PA on the surface of these cells.
The level of cell surface-associated PA of resting and activated neutrophils
was also compared using a monoclonal anti-uPA IgG and 12sI-labeled F(ab)2
fragments of anti-mouse IgG (P . Detmers, unpublished results) . It was deter-
mined that activated neutrophils bind approximately five to seven times more
anti-uPA IgG, confirming, by an independent approach, the presence of an
increased level of PA on the surface of activated neutrophils .HEIPLE AND OSSOWSKI
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TABLE IV
Generation ofPlasmin by Resting and PMA-activated Neutrophils
Neutrophils
￿
Incubation of cells Fibrinolytic
activity*
Resting
Activated
Aliquots (5 x 106/100 ul o£ phosphate buffer) of resting and activated
neutrophils were incubated for 30 min at 37'C with or without 1 mg/
ml of human plasminogen.
* cpm/ml x 10'
$ Before assaying for fibrinolytic activity, a fraction of each supernatant
taken from cellsincubated in buffer alonewas mixedwith andincubated
with plasminogen, using conditions identical to those described above.
The lack of activity in these samples indicates that no PA was released
into the supernatant of either resting or activated cells during the 30
min of incubation.
Discussion
By using the previously described procedure of neutrophil fractionation (13),
we have identified the fractions that contain theazurophilic granules, the specific
granules, and the plasma membranes and have assayed each fraction for PA
activity; most of the activity was found in the specific granules; only a small
amount was present in the plasma membrane (Table 1). PA activity was detected
only in neutrophils that were pretreated with DFP before fractionation (Fig. 1
and Table 1). Since PA is a serine protease, and therefore should be inhibited by
DFP, this findingmay seem paradoxical. However, our results (Table 111)showed
that PA was present in these cells in the form ofan amidolytically inactive pro-
enzyme that could not bind DFP (14, 22, 24) and consequently was protected
from inactivation by this compound .
Neutrophils are known to contain a number of different proteases, some of
them serine proteases (26-29). The plasminogen-independent activity of DFP-
treated cells was sevenfold less than that of untreated control cells (Fig. 4). In
individual Percoll gradient fractions, the level offibrinolytic activity was reduced
by 3-I1-fold. These results indicate that a large proportion of the fibrinolytic
activity is contributed by serine proteases such as elastase and chymotrypsin,
which are sensitive to DFP. It is likely that, when not inhibited, these activities
are responsible for the degradation ofneutrophil PA during fractionation.
As stated in Results, without DFP pretreatment a small proportion of PA (at
most 1% of that present in DFP-treated cells) was sometimes recovered; this
activity was always associated with the plasma membranes. In a number of
published studies of cells other than neutrophils, PA was found in the plasma
membrane or plasma membrane-like structures (8, 11, 12), but in view of our
findings, which clearly show that other cell proteases may have a crucial effect
on the quantity and the distribution of PA, these results should be reexamined.
Two points concerning the quantitation of PA in neutrophils should be
Without plasminogen* 0.0
With plasminogen 6.0
Without plasminogen* 0.0
With plasminogen 70.0836 TRANSLOCATION OF HUMAN NEUTROPHIL PLASMINOGEN ACTIVATOR
discussed. We found that the total PA activity of the cavitate (before it was
applied toa Percoll gradient) was only 40-60% of the sum of activities recovered
from the individual fractions (not shown) . This may be due to the presence of
inhibitors of PA which upon fractionation were distributed into separate (most
likely soluble) compartments . Such inhibitors have been shown to be present in
a number of cells, including macrophages (30) . The presence of inhibitors makes
the calculation ofenzyme recovery in different steps of fractionation somewhat
uncertain . Secondly, were active PA (in addition to pro-PA) present in the cells,
it would have been inactivated by the DFP pre-treatment, and we would have
no way of assessing what proportion of the total enzyme it might represent . This
does not seem to be the case, since in a number of recent reports using different
cells, it has been shown that PA is produced as an amidolytically inactive pro-
enzyme (14, 31-34), suggesting that this may be a general pathway of PA
synthesis ; neutrophils should not be different with respect to this property . In
addition, as shown in Table IV, the level of surface-associated PA activity of
resting neutrophils is very low, even in cells that have not been pretreated with
DFP. This finding indicatesthat thesubcellular distribution ofPA found in DFP-
pretreated cells reflects the genuine localization of this enzyme and does not
result from a selective inhibition by DFP of the surface, plasma membrane-
bound PA .
As shown in Results, before activation PA appears to be associated with the
membrane ofthespecific granules . Although the precise nature of this association
has not been identified, we found that treatment of the specific granules with
Triton X-100 enhances PA activity by three- to fivefold (data not shown) . This
suggests that PA is localized in the inner face of the specific granule membrane,
and that during fusion of the specific granules with plasma membrane, which is
a result of activation, it may become expressed on the extracellular face of the
plasma membrane . Our results support this possibility . We found that upon
activation, PA activity of the specific granules is reduced from 70 to 14% of total
(Fig . 5) . This reduction is very similar to that of vitamin B12-binding protein
(Fig . 5), a component of the specific granule matrix . However, in contrast to
vitamin B12-binding protein which can be quantitatively recovered from the
supernatant of the activated neutrophils, most of the PA (^-85% of total) in
activated neutrophils is found associated with the plasma membrane . This distri-
bution is very similar to that described for cytochrome-b, another component
associated with the membrane of neutrophil-specific granules (13) .
/3-glucuroidase, a marker for azurophilic granules, was undetectable in super-
natants from activated cells and was not noticeably reduced in the region of the
Percoll gradient containing azurophilic granules .
Low concentrations ofPMA causea selective exocytosis of the specific granules
(25) and result in PA accumulation in the neutrophil supernatants several hours
after treatment (1). We have shown that the appearance of PA on the surface of
the cells after activation is an early event that temporally precedes the release of
the enzyme into the supernatant . This was documented in fractionated cells that
were preexposed to DFP, a treatment that does not affect subsequent activation
(35), as well as in intact, untreated neutrophils (Table IV) . These results supportHEIPLE AND OSSOWSKI
￿
837
the theory suggesting that membrane-associated PA may have an important role
in processes requiring locally high levels ofproteolytic activity (4, 6, 7, 36).
The question of how the pro-uPA is initially converted to an active enzyme is
still under debate. Recent findings have shown that pro-uPA, which is inactive
in the amidolytic assay and unable to bind DFP, can activate plasminogen (22,
24, 37). Moreover, there are some indications (38) that membrane-bound PA
may be less sensitive to macromolecular inhibitors of proteases. Should these
findings be confirmed, they would mean that translocation of PA from the
specific granule to the plasma membrane would be all that is required to endow
the neutrophil surface with an important proteolytic activity .
Summary
The subcellular localization of plasminogen activator (PA) in human neutro-
phils was studied. The cells were disrupted by nitrogen cavitation and fraction-
ated on Percoll density gradients into three major components containing the
plasma membranes, the specific granules, and the azurophilic granules. The
biochemical markers we used to identify these organelles were alkaline phospha-
tase, vitamin B12-binding protein, and (3-glucuronidase, respectively . Using the
radioactive fibrin platemethod, PA activity and plasminogen-independent fibrin-
olytic activity were measured.
In resting neutrophils, PA was associated mainly with the membranes of the
specific granules. In fiveindividual experiments theactivity ofthisfraction varied
from 79 to 100% ofthe total; the remaining activity was found to be associated
with the plasma membrane, and no activity was present in the azurophilic
granules. In neutrophils that were activated by exposure to PMA (20 ng/ml for
15 min at 37'C), the total recoverable PA activity remained unchanged; however,
the main peak ofactivity (85% of total) shifted from the specific granules to the
plasma membranes. The magnitude ofthe reduction ofthe enzyme in thespecific
granules paralleled that of vitamin B12-binding protein. PMA-activated, intact
neutrophils had ^-12-fold more surface-bound PA activity than resting cells.
Recovery ofPA activity from neutrophils was critically dependent on pretreat-
ment of the intact cells with DFP before cavitation ; 100-fold more PA activity
was detected in DFP-pretreated cells. At the same time, this pretreatment
reduced the plasminogen-independent fibrinolytic activity by approximately
sevenfold. We determined that PA present in the neutrophils is of the urokinase
(UK) type and that the enzyme is produced and stored as a pro-UK, a form
insensitive to DFP inhibition. The reduction in the level ofproteases (measured
as fibrinolytic activity) and the resistance of pro-UK to DFP are most likely the
two major reasons for the greatly improved recovery of PA from the DFP-
pretreated cells.
These findings show that in resting neutrophils PA is stored in the specific
granules, and that during activation, it translocates to the outer surface of the
plasma membranes, thus equipping the cell with an ecto-proteolytic potential.
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